{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Aglatimagene_Besadenovec",
  "nciThesaurus": {
    "casRegistry": "1621271-62-2",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "An adenoviral vector engineered to express the herpes simplex virus thymidine kinase (HSV-tk) gene, which, when administered in conjunction with a synthetic acyclic guanosine analogue, possesses potential antineoplastic activity. Aglatimagene besadenovec is transduced into tumor cells, sensitizing tumor cells that overexpress HSV-tk to synthetic acyclic guanosine analogues. Subsequently, a low dose of a synthetic acyclic guanosine analogue such as valacyclovir (VCV) or ganciclovir (GCV) is given, which may preferentially kill tumor cells containing the adenoviral vector and overexpressing HSV-tk. Release of tumor-associated antigens (TAAs) by dying tumor cells may then stimulate an antitumor cytotoxic T lymphocyte (CTL) response.",
    "fdaUniiCode": "5Z72SSS34W",
    "identifier": "C73996",
    "preferredName": "Aglatimagene Besadenovec",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C129820",
      "C1962",
      "C61199"
    ],
    "synonyms": [
      "ADV-tk",
      "AGLATIMAGENE BESADENOVEC",
      "Aglatimagene Besadenovec",
      "GliAtak",
      "ProstAtak",
      "Virafir"
    ]
  }
}